Dexamethasone Resisted Podocyte Injury via Stabilizing TRPC6 Expression and Distribution

Area of Science:

• Nephrology
• Molecular Biology
• Cell Biology

Background:

• Podocytes are crucial for the kidney's filtration barrier.
• TRPC6 (Transient Receptor Potential Canonical 6) channels are vital for podocyte function.
• Dysfunctional podocytes and slit diaphragm (SD) integrity are linked to proteinuria.

Purpose of the Study:

• To investigate the role of TRPC6 in podocyte function and its relation to proteinuria.
• To explore the protective mechanisms of dexamethasone (DEX) on podocyte repair.

Main Methods:

• Overexpression of TRPC6 in podocytes using puromycin aminonucleoside (PAN).
• Assessment of podocyte foot process morphology, TRPC6 protein distribution, and mRNA expression.
• Evaluation of DEX treatment effects on TRPC6-overexpressing podocytes.

Main Results:

• TRPC6 overexpression significantly reduced podocyte foot processes.
• DEX treatment rescued these morphological changes by blocking TRPC6.
• DEX improved TRPC6 arrangement and decreased its mRNA and protein levels.

Conclusions:

• Overexpression of TRPC6 in podocytes contributes to slit diaphragm dysfunction and proteinuria.
• DEX protects podocyte structure and function by inhibiting the TRPC6 signaling pathway.
• DEX demonstrates potential as a therapeutic agent for anti-proteinuria in kidney diseases.